Phase I Clinical Trial of CVL218, a Novel PARP1/2 Inhibitor, in Patients with Advanced Solid Tumors

Zihong Chen & Yaxiong Zhang et al. · 2025

Links
Authors
Zihong Chen, Gang Chen, Yuxiang Ma, Hongyun Zhao, Jianhua Zhan, Yan Huang, Yunpeng Yang, Yuanyuan Zhao, Shaodong Hong, Ting Zhou, Wenfeng Fang, Li Zhang, Yaxiong Zhang